ALFA Finder| Revenue growth | INR 3,373 Cr in FY26 |
|---|---|
| Margins | EBITDA margin improved from 5.4% to 18.6% |
| Demand visibility | Strong for insulin and anti-MRSA brands |
| Management confidence | High regarding Zaynich US FDA/CDSCO approvals |
Growth
51% YoY EBITDA growth; Income at INR 3,373 Cr. Emrok grew ~50%; Biotech business grew 27%.
Outlook
Launching Zaynich in US, India, Europe; doubling Human Insulin capacity; deepening biosimilars pipeline.
Risks
Antimicrobial resistance challenges, IP risks, and R&D process uncertainties.
Last quarter's promises, checked
Delivered
- Guided 20% Zaynich superiority → delivered 20% (= BEAT)
- Guided INR 1000 Cr QIP → delivered INR 1000 Cr (= BEAT)
- Guided EBITDA growth >60% → delivered 67% (= BEAT)
Partly delivered
- Guided Zaynich US launch FY26-27 → delivered US FDA approval (= PARTIAL)
- Guided 2x Insulin capacity in 24mo → delivered 2x scale-up (= PARTIAL)
Missed
- Guided Net Debt:Equity 0.01% → delivered 0.10% (= MISS)
- Guided Revenue INR 3033 Cr → delivered INR 3373 Cr (= BEAT)
Earnings Call filed with NSE, NSE: WOCKPHARMA. Summary written with AI assistance from the document.
Wockhardt Ltd: key numbers
- Share price
- ₹2,034.60
- Market cap
- ₹33,065 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 80.7×Sector 43.8×
- Promoter holding
- 49.32%+0.24% QoQ
- FII holding
- 7.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Other Announcement
Wockhardt's monitoring agency report confirms no deviation in QIP proceeds use for the quarter ended September 30, 2026. It is routine periodic compliance with no financial event.
Wockhardt Management Change
Wockhardt designated Mr. Sumit Garg as Chief Digital & Information Officer, a Senior Management Personnel, from 02 November 2026. He brings over 30 years of technology and transformation leadership experience.
- Execution
- Full-time employment; term not time-bound
Wockhardt Results Update
Wockhardt reported Q2 FY27 PAT of Rs.73 Cr on revenue of Rs.969 Cr, up 24%. Biotech operations grew 68%, driven by emerging markets.
Wockhardt Q2 FY27 Results: Net Profit ₹73 Cr, Down 11.0% YoY
Wockhardt Ltd reported revenue from operations of ₹969 Cr (+23.9% YoY) and net profit of ₹73 Cr (-11.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹73 Cr · -11.0% YoY
Wockhardt Employee Stock Options
Wockhardt allotted 20,000 equity shares at Rs.5 exercise price under its ESOS 2011 scheme. Paid-up capital increases to 16,25,12,169 shares of Rs.5 each.
Wockhardt Board Meeting Date
Wockhardt Ltd intimated that its Board will meet on 2 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-declaration.